With 4.34 million shares changed hands, the volume of the stock remained lighter than its average volume of 6.1 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $0.245 whereas the lowest price it dropped to was $0.2211. The 52-week range on APDN shows that it touched its highest point at $14.40 and its lowest point at $0.12 during that stretch. It currently has a 1-year price target of $1.50. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APDN was up-trending over the past week, with a rise of 10.68%, but this was up by 41.88% over a month. Three-month performance dropped to -39.28% while six-month performance fell -50.22%. The stock lost -98.16% in the past year, while it has gained 11.76% so far this year.
Float and Shares Shorts:
At present, 52.29 million APDN shares are outstanding with a float of 52.28 million shares on hand for trading. On 2024-11-29, short shares totaled 1.77 million, which was 349.0 higher than short shares on 1730332800. In addition to Dr. James A. Hayward Ph.D., Sc.D. as the firm’s Chairman, President & CEO, Ms. Judith Murrah serves as its COO, Chief Information Officer & Secretary.
Institutional Ownership:
Through their ownership of 0.25015 of APDN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, APDN reported revenue of $813107.0 and operating income of -$3271255.0. The EBITDA in the recently reported quarter was -$3060270.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APDN since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$3.17133 being high and -$5.54867 being low. For APDN, this leads to a yearly average estimate of -$4.36.
